Surveillance of extended-spectrum β-lactamases from clinical samples and faecal carriers in Barcelona, Spain

被引:70
作者
Miró, E
Mirelis, B
Navarro, F
Rivera, A
Mesa, RJ
Roig, MC
Gómez, L
Coll, P
机构
[1] Hosp Santa Cruz & San Pablo, Microbiol Serv, E-08025 Barcelona, Spain
[2] Univ Autonoma Barcelona, Dept Genet & Microbiol, E-08193 Barcelona, Spain
关键词
ESBLs; CTX-M; SHV; PER-1;
D O I
10.1093/jac/dki395
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: The aim of the present study was to characterize and compare the extended-spectrum beta-lactamase (ESBL)-producing organisms isolated from clinical samples and faecal carriers in 2001 and 2002. Methods: A total of 5251 Enterobacteriaceae isolated from clinical samples and 1321 stool samples were evaluated for the presence of ESBLs. The stool samples were spread onto plates of MacConkey agar containing 2 mg/L cefotaxime for selection of ESBL-producing strains. These strains were defined as those showing synergism between amoxicillin/clavulanic acid and third-generation cephalosporins. The beta-lactamases involved were characterized by isoelectric focusing, PCR assays and DNA sequencing. Results: The prevalence of ESBL-producing strains among clinical Enterobacteriaceae was 1.7%. Of these, 87.6% produced CTX-M, 25.8% produced SHV and 2.2% were TEM-type-producing strains. All clinical ESBL-producing strains were Escherichia coli, with the exception of four Klebsiella pneumoniae and one Citrobacter freundii. The prevalence of faecal carriage of ESBL-producing organisms was 3.3%. Of these, 75% produced CTX-M-type enzymes followed by 22.7% SHV-producing strains. All faecal ESBL-producing strains were E. coli except for one Enterobacter cloacae and one Proteus mirabilis. This latter strain produced the PER-1 enzyme reported for the first time in Spain. Conclusions: The prevalence of ESBL-producing strains in stool samples was higher than that observed in clinical samples from the same period. The different types of ESBLs found were similar in both contexts. The most prevalent ESBLs were the CTX-M-related enzymes, with nine different types, followed by SHV-12.
引用
收藏
页码:1152 / 1155
页数:4
相关论文
共 10 条
[1]   Extended-spectrum β-lactamases in the 21st century:: Characterization, epidemiology, and detection of this important resistance threat [J].
Bradford, PA .
CLINICAL MICROBIOLOGY REVIEWS, 2001, 14 (04) :933-951
[2]   β-lactamases in ampicillin-resistant Escherichia coli isolates from foods, humans, and healthy animals [J].
Briñas, L ;
Zarazaga, M ;
Sáenz, Y ;
Ruiz-Larrea, F ;
Torres, C .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (10) :3156-3163
[3]  
Mirelis B, 2003, EMERG INFECT DIS, V9, P1024
[4]   Bacteriophages and diffusion of β-lactamase genes [J].
Muniesa, M ;
García, A ;
Miró, E ;
Mirelis, B ;
Prats, G ;
Jofre, J ;
Navarro, F .
EMERGING INFECTIOUS DISEASES, 2004, 10 (06) :1134-1137
[5]  
[NCCLS] National Committee for Clinical Laboratory Standards, 2002, M100S12 NCCLS
[6]  
Prats G, 2003, EMERG INFECT DIS, V9, P1273
[7]   Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients [J].
Rodríguez-Baño, J ;
Navarro, MD ;
Romero, L ;
Martínez-Martínez, L ;
Muniain, MA ;
Perea, EJ ;
Pérez-Cano, R ;
Pascual, A .
JOURNAL OF CLINICAL MICROBIOLOGY, 2004, 42 (03) :1089-1094
[8]   β-Lactamases involved in resistance to broad-spectrum cephalosporins in Escherichia coli and Klebsiella spp. clinical isolates collected between 1994 and 1996, in Barcelona (Spain) [J].
Sabaté, M ;
Miró, E ;
Navarro, F ;
Vergés, C ;
Aliaga, R ;
Mirelis, B ;
Prats, G .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 49 (06) :989-997
[9]   Dramatic increase in prevalence of fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain [J].
Valverde, A ;
Coque, TM ;
Sánchez-Moreno, MP ;
Rollán, A ;
Baquero, F ;
Cantón, R .
JOURNAL OF CLINICAL MICROBIOLOGY, 2004, 42 (10) :4769-4775
[10]   Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum β-lactamases in the UK [J].
Woodford, N ;
Ward, ME ;
Kaufmann, ME ;
Turton, J ;
Fagan, EJ ;
James, D ;
Johnson, AP ;
Pike, R ;
Warner, M ;
Cheasty, T ;
Pearson, A ;
Harry, S ;
Leach, JB ;
Loughrey, A ;
Lowes, JA ;
Warren, RE ;
Livermore, DM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 54 (04) :735-743